The detailed results from the HARMONi trial—the first global phase 3 data set for the world’s first PD-1xVEGF bispecific, ...
Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to exceed four years, surpassing monotherapy TKI osimertini ...
Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George ...
News-Medical.Net on MSN
Why universal COVID-19 vaccine guidance offers stronger protection than high-risk-only policies
The US Scenario Modeling Hub’s nine-team ensemble projected COVID-19 hospitalizations and deaths for April 2024 to April 2025 ...
Revolution Medicines, Inc. shares surged on strong Phase 1 data for daraxonrasib in metastatic pancreatic cancer. Click here ...
Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemothera ...
The Real Estate Debt Fund launched March 31, 2025. Institutional shares returned 2.02% during the second quarter, and the ...
Tom Nolan reviews this week’s research Aspirin is the first choice antiplatelet therapy for people with stable coronary heart disease. However, an individual patient data meta-analysis of seven ...
FLAURA2 phase III trial of AstraZeneca’s Tagrisso plus chemotherapy demonstrated a median overall survival in EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, September ...
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback